Determination of Biological Activity of Three Allergen Extracts

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

176 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-30

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Allergen extracts are complex mixtures of proteins and contain varying amounts of allergenic and non-allergenic components. Many factors such as the variability, differences in extraction process and subsequent handling of allergens can affect the final composition, potency, and stability of allergen preparations. Genetic diversity of affected people adds another level of complexity. In order to control variability and to achieve consistency and reproducibility for optimal safety and sensitivity/specificity, it is essential to standardize the amount of allergen used in prick tests. Therefore, the system for biological standardization mainly used in Europe still is the biological calibration of in-House Reference Preparations (IHRP). The method has been adopted by the Nordic Council on Medicines as the Nordic Biological Unit, Histamine Equivalent Potency (HEP) or Skin Prick Test (SPT) value. The aim of this procedure is to estimate the biological activity of allergen extracts. The activity of an allergen extract is defined as 1 SPT per ml, when the extract provokes a specific skin reaction with a wheal of the same size as a wheal provoked by reference histamine at a concentration of 10 mg/ml, when both solutions are administrated using the same technique (prick testing) on at least 20 individuals who are sensitized to the allergen concerned.

The present study aims to standardize the allergen extracts of Artemisia vulgaris, Platanus acerifolia, Dermatophagoides farinae by using this method.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biological Standardization of D. Glomerata, L. Perenne, S. Cereale and O. Europaea Pollen Extracts

NCT01567319

Sensitization to Allergens

COMPLETED PHASE1

Biological Standardization of Allergen Extracts of Pollens of Betula Pendula, Phleum Pratense and Mite Extract of Dermatophagoides Pteronyssinus

NCT01147159

Allergy

COMPLETED PHASE2

Biological Standardization of Dactylis Glomerata Allergen Extract

NCT01407835

Allergy to Grass Pollen (Dactylis Glomerata)

COMPLETED PHASE2

To Determine the Minimum Amount of Artemisia Vulgaris Allergen Extract Producing a Positive Skin Reaction.

NCT01984541

Allergy to Pollen

COMPLETED PHASE2

Phleum Pratense and Dactylis Glomerata Allergen Extracts Standardization

NCT06957496

Allergy Pollen Allergic Reaction Allergic Skin Reaction

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The present study aims to standardize the allergen extracts of Artemisa vulgaris, Platanus acerifolia and Dermatophagoides farinae by using this method. Standardized extracts will then be used for diagnostics and treatment of allergies as mentioned above.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypersensitivity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atopic subjects

Patients sensitized to other allergenic sources but the allergen extracts under investigation.

Group Type ACTIVE_COMPARATOR

Skin Prick Test - Atopic subjects

Intervention Type BIOLOGICAL

Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.

Non atopic subjects

Healthy volunteers

Group Type ACTIVE_COMPARATOR

Skin Prick Test - Non Atopic subjects

Intervention Type BIOLOGICAL

Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.

Allergic Subjects

Group Type OTHER

Skin Prick Test - Allergic subjects

Intervention Type BIOLOGICAL

Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Skin Prick Test - Atopic subjects

Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.

Intervention Type BIOLOGICAL

Skin Prick Test - Non Atopic subjects

Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.

Intervention Type BIOLOGICAL

Skin Prick Test - Allergic subjects

Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A. Subjects sensitized to one or more allergen extracts:

1. Positive clinical history with inhalant allergy to at least one of the allergen to be standardized.
2. At least one positive prick test (mean wheal diameter greater or equal than 3mm)
3. Positive prick test (wheal diameter greater or equal to 3 mm) to Histamine 10 mg/ml
4. Age: 18-60 years
5. Written informed consent
6. Patients will be:preferably be monosensitized, or with clinically relevant sensitization , or with primary sensitization (maximum cutaneous reactivity) to the extracts under investigation.Patient who belongs to one of the following group:

* Monosensitized patient to one of the extracts under investigation
* Patient with clinically relevant sensitization to the extracts under investigation.
* Patient with primary sensitization to one of the extracts under investigation
7. Women of child-bearing potential must have a negative urine pregnancy test at the time they begin the study.

B. Atopic Subjects:

1. Age: 18-60 years
2. Written informed consent
3. Positive prick test (wheal diameter greater or equal to 3 mm) to Histamine 10 mg/ml
4. Negative prick test (mean wheal diameter less or equal to 3mm) when tested with already standardized extracts of the allergens under investigation or with cross reactive extracts.
5. Women of child-bearing potential must have a negative urine pregnancy test at the time they begin the study.

C. No Atopic Subjects:

1. Age: 18-60 years.
2. Written informed consent
3. Positive prick test (wheal diameter greater or equal to 3 mm) to Histamine 10 mg/ml
4. Wheal diameter greater or equal to 3 mm for:

* Any allergen, except pollen for the cases of Artemisia vulgaris and/or Platanus acerifolia pollen extracts.
* Any allergen, except mites for the case of Dermatophagoides farinae mite extract.
5. In order to dismiss sensitization to other allergens, the wheal diameter should be less than 3 mm for:

* Any pollen (for the cases of Artemisia vulgaris and/or Platanus acerifolia pollen extracts)
* Any mites(for the case of Dermatophagoides farinae mite extract)
6. Women of child-bearing potential must have a negative urine pregnancy test at the time they begin the study.

Exclusion Criteria

1. Immunotherapy in the 5 years prior to the study against either the allergen to be tested or an allergen which is cross-reactive. (it is not applicable to no atopic patients)
2. Any drug which may interfere with the cutaneous test or with its result.
3. Any medical condition that from investigator's point of view the skin prick test cannot be done .
4. Women who are pregnant or breast-feeding or are child-bearing age and who have not demonstrated that they have been surgically sterilized or have other means of not bearing children.
5. Subjects who have participated in another clinical trial within 3 months prior to this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes